Nervgen Pharma Corp. · NASDAQ:NGEN
Nervgen Pharma — Investor Presentation (April 2025)
25 slides from Nervgen Pharma's investor presentation, Apr 28, 2025
Slide 1: Enabling the Nervous System to Repair Itself
Enabling the Nervous System to Repair Itself Corporate Presentation April 2025
Slide 2: Financial Disclosure Statement
Financial Disclosure Statement Not an offer or solicitation: This document is provided for general information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. The contents of this document have not been approved or disappr
Slide 3: First-in-Class Neuro-Reparative Therapeutics for Spinal Cord Injury
First-in-Class Neuro-Reparative Therapeutics for Spinal Cord Injury • A leading spinal cord injury (SCI) company targeting chondroitin sulfate proteoglycan-mediated inhibition of neural repair • Lead asset (NVG-291) is a subcutaneously administered, cell-penetrating peptide in an ongoing Phase 1b/2a
Slide 4: The Mechanistic Rationale of NVG-291
The Mechanistic Rationale of NVG-291 Thoracic Staining at 12 Weeks Post-Injury Shows Serotonergic Axon Sprouting Chondroitin sulfate proteoglycans (CSPGs) are extracellular matrix molecules widely Rostral (above injury) Rostral (above injury) expressed in the central nervous system as inhibitory cue
Slide 5: NVG-291-R Promotes Functional Recovery in Acute Models
NVG-291-R Promotes Functional Recovery in Acute Spinal Cord Injury Models Overview Hindlimb Function • T8 compression injury 21 = Normal function 20 Treatment Period • Treatment start: 1-day post-injury **** **** • Dose: 500 µg/day x 7 weeks **** 15 **** NVG-291-R (N=10) ≥14 = Fine motor skill BBB S
Slide 6: NVG-291-R Promotes Functional Recovery in Chronic Models
NVG-291-R Promotes Functional Recovery in Chronic Spinal Cord Injury Models Overview Forelimb Function • C2 lateral hemi-section model of SCI 14 Treatment Period *** • Treatment start: 12 weeks post-injury 12 * ** Forelimb Locomotor Rating • Dose: 500 µg/day x 8.5 weeks 10 8 Scale Results 6 • Signif
Slide 7: NVG-291-R Improves Bladder Control in Models
NVG-291-R Improves Bladder Control in Spinal Cord Injury Models Bladder Dose Response 1.5 100% Void Frequency (voids / hour) ** * of animals in the two highest dose cohorts had improved 1.0 Responders bladder control function (2x SD of vehicle mean) • Animals tested at week 12 post-SCI; graph shows
Slide 8: NVG-291-R Improves Motor Function in Severe Models
NVG-291-R Improves Motor Function in Severe Spinal Cord Injury Models Placebo Group After Treatment Play with solid fill Click here to play video Click here to play video 8 Rink, S. et al., Experimental Neurology 309, 148–159 (2018)
Slide 9: Spinal Cord Injury Demographics and Characteristics in the U.S.
Spinal Cord Injury Demographics and Characteristics in the U.S. • Average Age: 44 • Male (78%), Female (22%) • Cause: Vehicle (37%), Fall (32%), Violence (15%), Sports (8%) • Annual Re-Hospitalization (30%): UTI, Pneumonia, Decubitus Ulcers • Significant Urinary and Sexual Dysfunction • Duration of
Slide 10: Current Standard of Care for Spinal Cord Injury
Current Standard of Care for Spinal Cord Injury Decompression Surgery Rehabilitation No Approved Drugs Enable Functional Recovery • Plateau of spontaneous functional recovery after 6-9 months1 • Shift in priorities from full recovery to quality of daily living, including: • Ability to self-feed; con
Slide 11: The Economic Burden of Spinal Cord Injury in the U.S.
The Economic Burden of Spinal Cord Injury in the U.S. Cost per Patient1 Cost to the System1,2,3 $1M-$6M in lifetime care costs ~$58B in total annual cost to depending on severity or age at injury the healthcare system $1.2M average care costs in the ~$15B of medical and related costs first year of i
Slide 12: Untapped Market Opportunity with No Approved Therapies
Untapped Market Opportunity with No Approved Therapies Spinal cord injury affects ~12M people worldwide, with 285K new cases every year U.S. Market Breakdown 1 Total U.S. SCI Patients ~$60-80B U.S. Prevalence: ~310K U.S. Incidence: ~18.5K Total U.S. Cervical Patients ~$40-50B U.S. Prevalence: ~165K
Slide 13: NVG-291 Phase 1 Clinical Trial in Healthy Volunteers
NVG-291 Phase 1 Clinical Trial in Healthy Volunteers Study Design Safety Results Single Dose • Well tolerated across all doses • 37 subjects − Maximum tolerated dose not reached • 6 dose levels • No treatment discontinuations • Assessed through Day 8 Multiple Dose • No serious/severe adverse events
Slide 14: Clinical Objective: NVG-291 Increases Connectivity after Spinal Cord Injury
Clinical Objective: NVG-291 Increases Connectivity after Spinal Cord Injury Preclinical Rodent variant of NVG-291 (NVG-291-R/ISP) demonstrates axonal regeneration, remyelination, Studies enhanced plasticity and nervous system repair Clinical NVG-291 increases connectivity and motor function in human
Slide 15: Phase 1b/2a Trial Design in Chronic and Subacute Spinal Cord Injury
Phase 1b/2a Trial Design in Chronic and Subacute Spinal Cord Injury Δ in MEP Amplitude and Clinical Function No NVG-291 Daily Subcutaneous Injections Intervention Screening No Placebo Daily Subcutaneous Injections Intervention Assessments: Baseline Week 2 Week 4 Week 8 Week 12 Week 16 + Rehabilitati
Slide 16: Phase 1b/2a Electrophysiological Endpoints
Phase 1b/2a Electrophysiological Endpoints Change in Motor Evoked Potential Amplitude (MEP) of First Dorsal Interosseous Muscle (FDI) Change in Motor Evoked Potential Amplitude (MEP) of Tibialis Anterior Muscle (TA) Preclinical Evidence: Improvements in MEPs Correlate to Forelimb Recovery1 Two Injur
Slide 17: SCI Results in Loss of Connectivity, Reflected by Reduced MEP Amplitudes
SCI Results in Loss of Connectivity, Reflected by Reduced MEP Amplitudes Motor evoked potentials (MEPs) are measured via electrical stimulation of the corticospinal pathway Brain Corticospinal Pathway Spinal Cord Peripheral Nerve Normal Motor Evoked Potential After Spinal Cord Injury Muscle Reduced
Slide 18: NVG-291 Seeks to Improve Connectivity, Reflected by Increased MEP Amplitudes
NVG-291 Seeks to Improve Connectivity, Reflected by Increased MEP Amplitudes First Dorsal Interosseus (FDI) Goal of NVG-291: Increase Motor Connectivity & MEP Amplitudes (finger control, grasping) FDI TMS Electrical stim (ES) Electrical stim (ES) Hand 1 mV Leg 20 ms Tibialis Anterior (TA) (walking)
Slide 19: Phase 1b/2a Functional (Clinical) Endpoints
Phase 1b/2a Functional (Clinical) Endpoints Ten Meter Walk Test (10mWT) 9-Hole Peg Test (9-HPT) Pinch Force GRASSP (Graded Redefined Assessment of Strength, Sensation and Prehension) Lower Extremity Motor Score (LEMS) Upper Extremity Motor Score (UEMS) 10mWT 9-HPT Pinch Force GRASSP LEMS UEMS L2 Hip
Slide 20: Comprehensive Intellectual Property Coverage of NVG-291
Comprehensive Intellectual Property Coverage of NVG-291 High confidence of exclusivity through composition of matter, method of use, orphan designation, and other • Exclusive worldwide rights to NVG-291 composition and all indications, licensed from Case Western Reserve University • Composition of m
Slide 21: Development Pipeline and Near-Term Milestones
Development Pipeline and Near-Term Milestones Candidate Program Discovery Preclinical Phase 1 Phase 1b/2a Spinal Cord Injury NVG-291 Ischemic Stroke Ischemic Stroke Amyotrophic Lateral Sclerosis NVG-300* Alzheimer's Disease Multiple Sclerosis • Phase 1b/2a Topline Data in Chronic SCI: Early June 202
Slide 22: Share and Capital Structure
Share and Capital Structure Exchange/Market: Ticker TSX: NGEN.V OTCQB: NGENF Recent Share Price (Apr 28, 2025) CA$2.97 / US$2.15 Shares Outstanding 71.2 million Fully Diluted 95.0 million (~13.7 million options & retention securities, ~10.1 million warrants*) Insider Ownership 20.9% Cash & Cash Equi
Slide 23: Seasoned Leadership Team
Seasoned Leadership Team MIKE KELLY, MBA, CHIEF EXECUTIVE OFFICER Over 30 years of pharmaceutical experience. Formerly President of US Ops for Adapt Pharma, Inc., which developed and commercialized NARCAN Nasal Spray in the US and Canada and was sold to Emergent BioSolutions for US$735 million. BILL
Slide 24: Board of Directors
Board of Directors Glenn Ives Chairman Former Partner, Deloitte LLP Harold Punnett, DMD Mike Kelly Adam Rogers, MD Co-Founder Former CEO & Co-Founder, Hemera President & CEO, NervGen Brian Bayley Neil Klompas John Ruffolo Director, Earlston Investments President & CEO, Augurex Founder & Managing Par
Slide 25: Enabling the Nervous System to Repair Itself
Enabling the Nervous System to Repair Itself www.nervgen.com Certain images in this presentation are sourced from Flaticon All trademarks are the property of their respective Company owners